Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:cisplatin
|
| gptkbp:activities |
DNA cross-linking
|
| gptkbp:appointed_by |
intravenous injection
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Cisplatin Injection
Platinol-AQ |
| gptkbp:clinical_trial |
Phase II
Phase III |
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to cisplatin |
| gptkbp:developed_by |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:discovered_by |
1970s
|
| gptkbp:displacement |
from plasma proteins
|
| gptkbp:education |
reporting side effects
avoidance of live vaccines hydration before treatment |
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
sterile solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
Platinol
|
| gptkbp:indication |
gptkb:healthcare_organization
ovarian cancer bladder cancer |
| gptkbp:ingredients |
gptkb:cisplatin
C6 H6 Cl2 N4 O4 Pt |
| gptkbp:interacts_with |
with aminoglycosides
with loop diuretics with other nephrotoxic agents |
| gptkbp:is_monitored_by |
renal function
hearing tests blood counts |
| gptkbp:is_used_for |
treating cancer
|
| gptkbp:lifespan |
30 minutes to 3 hours
|
| gptkbp:manager |
IV
|
| gptkbp:metabolism |
not extensively metabolized
|
| gptkbp:risk_factor |
nephrotoxicity
ototoxicity myelosuppression |
| gptkbp:side_effect |
nausea
vomiting hearing loss kidney damage |
| gptkbp:storage |
room temperature
|
| gptkbp:traded_on |
Cisplatin
|
| gptkbp:treatment |
with gemcitabine
with paclitaxel |
| gptkbp:weight |
300.05 g/mol
|